McCain Tracey L — SEC Form 4 filings
SEC reporting owner CIK 1683600. 9 Form 4 filings on record with FilingPulse; latest filed 2026-06-02.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-02-12 to 2026-06-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 10,456 shares, $938,309 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 34.
- Largest priced transaction: sale of 5,194 shares @ $90.69 ($471,044) in Blueprint Medicines Corp, filed 2024-03-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Blueprint Medicines Corp (BPMC) | EVP & Chief Legal Officer | 5 | — | 2 legs · 10,456 sh · $938,309 | 17 |
| Kiniksa Pharmaceuticals International, plc (KNSA) | Director | 3 | — | — | 12 |
| ImmunoGen, Inc. (IMGN) | Director | 1 | — | — | 5 |
Form 4 filings — McCain Tracey L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-02 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 2,799 · Grant/award (A): 12,158 (derivative) @ $0 · Grant/award (A): 2,026 (derivative) @ $0 · Option exercise (M): 2,799 (derivative) @ $0 | EDGAR |
| 2025-07-21 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 21,353 · Disposition to issuer (D): 51,103 · Code (U): 37,092 · Disposition to issuer (D): 55,000 (derivative) · Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 39,000 (derivative) · +7 more | EDGAR |
| 2025-06-05 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 3,173 · Grant/award (A): 16,798 (derivative) @ $0 · Grant/award (A): 2,799 (derivative) @ $0 · Option exercise (M): 3,173 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Blueprint Medicines Corp (BPMC) | Sale (S): 5,262 @ $88.80 | EDGAR |
| 2025-03-04 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 11,000 @ $0 · Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 4,373 · Grant/award (A): 19,040 (derivative) @ $0 · Grant/award (A): 3,173 (derivative) @ $0 · Option exercise (M): 4,373 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Blueprint Medicines Corp (BPMC) | Sale (S): 5,194 @ $90.69 | EDGAR |
| 2024-03-06 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 12,500 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | ImmunoGen, Inc. (IMGN) | Disposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 50,303 (derivative) · Disposition to issuer (D): 19,597 (derivative) · Disposition to issuer (D): 25,556 (derivative) · Disposition to issuer (D): 44,000 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1683600 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →